Skip to main content
BMC Cancer logoLink to BMC Cancer
. 2016 Apr 15;16:272. doi: 10.1186/s12885-016-2309-y

Erratum to: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma

Yusuke Okuma 1,2,, Yukio Hosomi 1, Shingo Miyamoto 3, Masahiko Shibuya 1, Tatsuru Okamura 1, Tsunekazu Hishima 4
PMCID: PMC4833961  PMID: 27084341

Erratum

Following publication of this work [1] the authors noticed a mistake within the article’s competing interests section. The correct competing interests section is provided below.

Footnotes

The online version of the original article can be found under doi:10.1186/s12885-016-2159-7.

Competing interests

The authors declare that they have no competing interests. This study is supported by the grant for the Clinical Research of Tokyo Metropolitan Hospital and Taiho Pharmaceutical Inc. who analyzed the thymidine synthase, thymidine phosphorylase, orotate phosphoribosyltransferase, and dihydropyrimidine dehydrogenase using RT-PCR.

Reference

  • 1.Okuma Y, Hosomi Y, Miyamoto S, Shibuya M, Okamura T, Hishima T. Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. BMC Cancer. 2016;16:156. doi: 10.1186/s12885-016-2159-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Cancer are provided here courtesy of BMC

RESOURCES